TY - JOUR
T1 - Dosing of Mood Stabilizers for Bipolar Disorder Patients in the Research on Asian Psychotropic Prescription Patterns Consortium Study
AU - Wang, Yuxi
AU - Chew, Qian Hui
AU - Lin, Shih Ku
AU - Yang, Shu Yu
AU - Ouyang, Wen Chen
AU - Chen, Chih Ken
AU - Park, Seon Cheol
AU - Jang, Ok Jin
AU - Park, Jun Hyuk
AU - Chee, Kok Yoon
AU - Ding, Kwong Sen
AU - Chong, Jamaline
AU - Zhang, Ling
AU - Li, Keqing
AU - Zhu, Xiaomin
AU - Jatchavala, Chonnakarn
AU - Pariwatcharakul, Pornjira
AU - Kallivayalil, Roy Abraham
AU - Grover, Sandeep
AU - Avasthi, Ajit
AU - Ansari, Moin
AU - Maramis, Margarita M.
AU - Aung, Paing Phyo
AU - Sartorius, Norman
AU - Xiang, Yu Tao
AU - Tan, Chay Hoon
AU - Chong, Mian Yoon
AU - Park, Yong Chon
AU - Kato, Takahiro A.
AU - Shinfuku, Naotaka
AU - Baldessarini, Ross J.
AU - Sim, Kang
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Background Because use and dosing of mood stabilizers (MSs) to treat bipolar disorder (BD) patients in Asia are not well documented, we examined prevalence and clinical correlates of treatment of Asian BD patients with relatively high doses of MSs. Methods We conducted a pharmacoepidemiological survey across 13 Asian countries and territory in the Research on Asian Psychotropic Prescription Patterns Consortium. Mood stabilizer doses were converted to lithium carbonate equivalents (Li-eq milligrams per day). We compared relatively high (>900 Li-eq mg/day) versus lower MS doses by bivariate comparisons, followed by multivariable linear regression to identify factors associated with higher MS doses. Results Among 1647 participants, MS dose averaged 584 (confidence interval, 565-603 Li-eq mg/d). Preliminarily, the 13.1% of the subjects given greater than 900 mg/d versus those given lower doses were younger, male, currently hospitalized, not currently depressed, and reported lifetime suicidal ideation; they also received relatively high doses of antipsychotics, received electroconvulsive treatment within the previous 12 months, and had greater ratings of tremors and sedation. By linear regression modeling, the mean proportion given high doses of MS was associated significantly and independently with higher doses of antipsychotics, younger age, male sex, hospitalized, more years of illness, country, higher body mass index, recent electroconvulsive treatment, and being in illness remission. Conclusions Relatively high doses of MSs for BD are prevalent, but vary markedly among Asian countries, and are particularly likely among young males, ill for many years, and given high doses of antipsychotics or ECT. These characteristics allow better identification of patient profiles that can guide treatment of BD patients.
AB - Background Because use and dosing of mood stabilizers (MSs) to treat bipolar disorder (BD) patients in Asia are not well documented, we examined prevalence and clinical correlates of treatment of Asian BD patients with relatively high doses of MSs. Methods We conducted a pharmacoepidemiological survey across 13 Asian countries and territory in the Research on Asian Psychotropic Prescription Patterns Consortium. Mood stabilizer doses were converted to lithium carbonate equivalents (Li-eq milligrams per day). We compared relatively high (>900 Li-eq mg/day) versus lower MS doses by bivariate comparisons, followed by multivariable linear regression to identify factors associated with higher MS doses. Results Among 1647 participants, MS dose averaged 584 (confidence interval, 565-603 Li-eq mg/d). Preliminarily, the 13.1% of the subjects given greater than 900 mg/d versus those given lower doses were younger, male, currently hospitalized, not currently depressed, and reported lifetime suicidal ideation; they also received relatively high doses of antipsychotics, received electroconvulsive treatment within the previous 12 months, and had greater ratings of tremors and sedation. By linear regression modeling, the mean proportion given high doses of MS was associated significantly and independently with higher doses of antipsychotics, younger age, male sex, hospitalized, more years of illness, country, higher body mass index, recent electroconvulsive treatment, and being in illness remission. Conclusions Relatively high doses of MSs for BD are prevalent, but vary markedly among Asian countries, and are particularly likely among young males, ill for many years, and given high doses of antipsychotics or ECT. These characteristics allow better identification of patient profiles that can guide treatment of BD patients.
KW - Asia
KW - Bipolar disorder
KW - Doses
KW - Mood stabilizers
UR - http://www.scopus.com/inward/record.url?scp=85129373833&partnerID=8YFLogxK
U2 - 10.1097/JCP.0000000000001549
DO - 10.1097/JCP.0000000000001549
M3 - 文章
C2 - 35384905
AN - SCOPUS:85129373833
SN - 0271-0749
VL - 42
SP - 293
EP - 297
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 3
ER -